Karwanje Pratik M.*, Bhawar Sanjay B. and Kakad Sudarshan B.


Ranolazine is a piperazine derivative accepted as an antianginal drug. Principally it is used as a second line antianginal in stable coronary artery disease. Ranolazine blocks the late Na + current and prevents the rise of cytosolic calcium. It decreases myocardial wall tension and improves coronary blood flow. Ranolazine is effective in atrial fibrillation (AF) as an appendage to electrical or pharmacological cardio version. It can be used in permutation with amiodarone, metoprolol or dronedarone. It has also been used in AF arising after coronary artery bypass grafting surgery. Role of ranolazine is also being evaluated in pulmonary arterial hypertension, diastolic dysfunction, and chemotherapy induced cardio toxicity. Ranolazine has some antiglycemic effect and has shown a reduction of hemoglobin A1C in several trials. The antianginal effect of ranolazine has also been seen to be more in patients with diabetes compared to those without diabetes. Ranolazine is being evaluated in patients with the peripheral arterial disease with discontinuous claudication and hypertrophic cardiomyopathy. Pilot studies have shown that Ranolazine may be beneficial in neurological conditions with myotonia. The evidence base on the use of ranolazine in various circumstances is rapidly increasing with results of further trials readily awaited. Accumulating verification may see Ranolazine in schedule clinical use for many conditions beyond its traditional role as an antianginal.

Keywords: Ranolazine, angina, anti ischemic.

[Full Text Article]   [Download Certificate]


Forgot Password  |  Register


Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Dr. Dhrubo Jyoti Sen

Download Article : Click here

News & Updation


    JULY 2024 Issue has been successfully launched on 1 JULY 2024.

  • EJBPS New Impact Factor

    EJBPS Impact Factor has been Increased to 7.482 for Year 2024.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.


UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS


Copyright From

Covering Letter

                        Author Instruction